STAT+: With $173 million, new startup takes aim at sickle cell
Researchers are seeking a sickle cell treatment as effective as gene therapy, without the drawbacks. This entrepreneur thinks he might have one.
STAT PlusBiotech With $173 million, new startup takes aim at sickle cell Marrow Therapeutics is trying to build an infusion as effective as gene therapy Manage alerts for this article Save this story for later Share this article By Jason MastNov. 17, 2026 General Assignment Reporter Jason Mast[email protected]Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.
For years, researchers and investors have been searching for a treatment that’s as effective in treating sickle cell disease as gene therapy — but without the many drawbacks. Biotech entrepreneur Romesh Subramanian thinks he might have one. On Tuesday, he announced the founding of new startup Marrow Therapeutics to pursue it, with $173 million in Series A and B funding from Scion Life Sciences, venBio, OrbiMed and others.Advertisement “We expect it to be as good as [gene therapy] in patients,” Subramanian said, “but to be proven for sure.” STAT+ Exclusive Story Already have an account?
Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%!
Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, rare diseases, STAT+ Submit a correction requestReprints Jason Mast General Assignment Reporter Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease.
Confidential tips can be sent on Signal at JasonMast.77. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech November 17, 2026 STAT Plus: After death in gene therapy trial for a brain disease, progress is reported Pharma November 16, 2026 STAT Plus: In a win for MAHA, FDA creates new regulatory category for the supplement NAC Advertisement The Readout November 16, 2026 STAT Plus: Biotech’s rebound isn’t lifting all boats equally Biotech November 16, 2026 STAT Plus: Helus’ psychedelic drug improved depression in study but faces safety questions Biotech November 16, 2026 STAT Plus: Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence Subscriber Picks
comments(0)
5-min edit window · permanent after that